All In Biotech

BLA 103846 · Elan Pharm

Myobloc

Botulinum Toxin Type B · Acetylcholine Release Inhibitor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Mar 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Dec 8, 2000

Approved uses

2

Original approval plus efficacy supplements

Registered trials

90

26 Phase 3, 3 recruiting

FAERS reports

328

188 serious, 58 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and...

What it is approved for

From the label in effect Oct 5, 2026.

MYOBLOC is an acetylcholine release inhibitor indicated for: Treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults ( 1.1 ) Treatment of chronic sialorrhea in adults ( 1.2 ) 1.1 Cervical Dystonia MYOBLOC is indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults. 1.2 Chronic Sialorrhea MYOBLOC is indicated for the treatment of chronic sialorrhea in adults.

Mechanism: MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerved terminals. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin), a presynaptic target protein essential...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MYOBLOC · Botulinum Toxin Type B 5000IU/VIAL · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Botulinum Toxin Type B" as an intervention, any sponsor and status, largest first.

All 90 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dry mouth46
  • dysphagia43
  • death42
  • product use in unapproved indication34
  • drug ineffective30
  • headache23
  • vision blurred22
  • off label use21
  • dyspnoea15
  • constipation14
  • nausea14
  • neck pain14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
20055
200613
200711
20088
20097
20105
20111
20123
20134
20143
20157
20166
201716
201820
201915
202016
202123
202228
202324
202429
202532
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Myobloc (Rimabotulinumtoxinb)

2024 spending

$855K

Beneficiaries

445

1,022 claims

Per beneficiary

$1,922

$613.43 per unit

View as table
YearSpending
2020$542,443
2021$664,082
2022$865,535
2023$914,593
2024$855,300

Part B: Myobloc (Rimabotulinumtoxinb) · HCPCS J0587

2024 spending

$7.6M

Beneficiaries

3,611

8,670 claims

Per beneficiary

$2,108

2024 ASP limit $13.03 per unit

View as table
YearSpending
2020$7,358,589
2021$7,593,699
2022$7,514,865
2023$7,453,598
2024$7,611,544

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 62 on PubMed

Sponsor: Elan Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.